查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
呼吸系统用医药品的全球市场(2022年～2028年)
市场调查报告书
商品编码
1123208

呼吸系统用医药品的全球市场(2022年～2028年)

Global Respiratory Drug Market Research and Forecast 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

全球呼吸系统用医药品的市场规模在预测期间内预计将以年复合成长率6.5％成长。慢性呼吸道疾病的流行是影响和推动市场的因素之一。此外，新产品开发的进展和小儿呼吸道疾病病例的增加也被认为是对市场增长做出重大贡献的因素。

本报告提供全球呼吸系统用医药品市场相关调查分析，提供市场区隔分析，地区分析，预测，企业简介等资讯。

目录

第1章 报告摘要

第2章 与市场概要考察

第3章 竞争情形

  • 主要企业分析
    • 概要
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 主要策略分析
  • COVID-19对主要企业的影响

第4章 市场决策要素

  • 促进因素
  • 阻碍因素
  • 机会

第5章 市场区隔

  • 全球呼吸系统用医药品市场:各给药途径
    • 口服
    • 注射可能
    • 吸入可能
  • 全球呼吸系统用医药品市场:各用途
    • 气喘
    • 慢性阻塞性肺病（COPD）
  • 全球呼吸系统用医药品市场:各终端用户
    • 居家照护
    • 医院·诊疗所

第6章 地区分析

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 其他的欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他的亚太地区
  • 其他地区

第7章 企业简介

  • Air Liquide
  • AstraZeneca
  • Bausch Health Companies Inc.
  • Baxter
  • Beximco Pharmaceuticals Ltd.
  • Boehringer Ingelheim International GmbH.
  • Compumedics Ltd.
  • Medtronic
  • Dragerwerk AG & Co. KGaA
  • F. Hoffmann-La Roche Ltd
Product Code: OMR2018324

Global Respiratory Drug market By Route of Administration (Oral, Injectable and Inhalable), By Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), and By End-User (Homecare and Hospitals and Clinics) Forecast Period (2021-2027)

The global respiratory drug market is growing at a considerable CAGR of 6.5% during the forecast period. Increasing pervasiveness of chronic respiratory diseases is one of the prime factors affecting and driving the market. Increasing development of new products and increasing number of cases in children related to respiratory diseases is also estimated to be the prime factors that are contributing significantly towards the growth of the market. However, strict government rules and regulations are major factors constraints that are hindering the growth of the global respiratory drug market across the globe.

However, increasing demand for home care products is one of the key factors that are creating opportunity for the market. New product launches in the market are likely to drive the growth of the global respiratory drug market. For instance, in September 2020, Verona Pharma plc one of the companies that is clinical stage bio-pharmaceutical which emphasis on diseases related to respiratory had set forth the symptom data related to phase 2b Chronic Obstructive Pulmonary Disease (COPD). This was done in international journal of Chronic Obstructive Pulmonary Disease which highlighted the fact through this data that ensifentrine had produced improvements in functionality of lung through its all doses along with progressive betterment in symptoms related to Chronic Obstructive Pulmonary Disease.

Impact of COVID-19 on the Global Respiratory drug market

The global respiratory drug market is hardly hit by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in the major economies had disrupted the manufacturing and transportation activities. However, with the lockdown restriction lifted it is likely to increase the output for respiratory drug devices for patients.

Segmental Outlook

The market is segmented based on route of administration, application and end-user. Based on route of administration, the market is segmented into oral, injectable and inhalable. By application, the market is segmented into asthma and chronic obstructive pulmonary disease (COPD). By end-user, market is segmented into homecare and hospitals and clinics.

Global Respiratory drug market Share by End- User 2020 (%)

Global Respiratory drug market Share by End- User

Based on the end-user, hospitals and clinics holds a significant share in the market. Respiratory drug along with device are mostly used and needed in the hospitals for providing proper treatment to the patient. Initially, most of the products in healthcare sector are designed for the hospitals only. Generally, the requirement of hospitals with regards to equipment related to respiratory are of two types. Firstly that can be used in emergency situations such as in ambulance and secondly it can be fixed equipment that is used in hospitals. The manufacturing company provides the equipment that are having longer life cycle with better effectiveness.

Regional Outlooks

The global respiratory drug market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held a considerable share in 2020 in the global respiratory drug market. Some factors that are boosting the market growth in North America are growing geriatric population, leading manufactures and players present in the region. Additionally, increasing pervasiveness of chronic respiratory diseases along with technology advancement is some other factors that are promoting the growth of the market.

Global Respiratory Drug market, by Region 2021-2027

Global Respiratory Drug market, by Region

Asia-Pacific will have Considerable Growth in the Global Respiratory Drug market

Asia-Pacific region is expected to witness significant growth opportunities for the market. Large scale population affected with asthma and chronic obstructive pulmonary disease along with increasing awareness regarding the treatment of the asthma and chronic obstructive pulmonary disease in the region are likely to drive the growth of the regional market. Further due to rising health care expenditure along with increasing R&D by market player in India, China and South Korea are also some of the factors that are affecting and impacting the growth in this market.

Market Player Outlook

Key players of the global respiratory drug market are AstraZeneca, Boehringer Ingelheim International GmbH., GlaxoSmithKline plc. Koninklijke Philips N.V., and OMRON corp., among others. To survive in the market, these players adopt different marketing strategies such as product launches, collaboration. For instance, in July 2020, Novartis AG has put forward the results from second phase IRIDIUM study. This study result indicates that one daily treatment dose which is high and medium of enerzair; breezhaler had highlighted the improvement in functionality of lung along with asthma.

In June2019, Theravance Biopharma along with Mylan N.V. had entered into agreement in order to expand the development and commercialization regards to nebulized bronchodilator in China. Revefenacin is offered with the name Yupelri that is one in a day to be used nebulized bronchodilator for which it had also got the approval in the US for Chronic Obstructive Pulmonary Disease (COPD). Moreover, now it will give effective treatment to around 100 million patients suffering from Chronic Obstructive Pulmonary Disease (COPD) in China.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global respiratory drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Respiratory Drug Industry
  • Recovery Scenario of Global Respiratory Drug Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Respiratory Drug Market by Route of Administration
    • 5.1.1. Oral
    • 5.1.2. Injectable
    • 5.1.3. Inhalable
  • 5.2. Global Respiratory Drug Market by Application
    • 5.2.1. Asthma
    • 5.2.2. Chronic Obstructive Pulmonary Disease (COPD)
  • 5.3. Global Respiratory Drug Market by End-User
    • 5.3.1. Homecare
    • 5.3.2. Hospitals and Clinics

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Air Liquide
  • 7.2. AstraZeneca
  • 7.3. Bausch Health Companies Inc.
  • 7.4. Baxter
  • 7.5. Beximco Pharmaceuticals Ltd.
  • 7.6. Boehringer Ingelheim International GmbH.
  • 7.7. Compumedics Ltd.
  • 7.8. Medtronic
  • 7.9. Dragerwerk AG & Co. KGaA,
  • 7.10. F. Hoffmann-La Roche Ltd **List not exhaustive

LIST OF TABLES

  • 1. GLOBAL RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL RESPIRATORY DRUG MARKET BY ROUTE OF ADMINISTRATION, 2020-2027($ MILLION)
  • 3. GLOBAL ORAL RESPIRATORY DRUG MARKET BY REGION, 2020-2027($ MILLION)
  • 4. GLOBAL INJECTABLE RESPIRATORY DRUG MARKET BY REGION, 2020-2027($ MILLION)
  • 5. GLOBAL INHALABLE RESPIRATORY DRUG MARKET BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL RESPIRATORY DRUG MARKET BY APPLICATION, 2020-2027($ MILLION)
  • 7. GLOBAL ASTHMA RESPIRATORY DRUG MARKET BY REGION, 2020-2027($ MILLION)
  • 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) RESPIRATORY DRUG MARKET BY REGION, 2020-2027($ MILLION)
  • 9. GLOBAL RESPIRATORY DRUG MARKET BY END-USER, 2020-2027($ MILLION)
  • 10. GLOBAL HOMECARE RESPIRATORY DRUG MARKET BY REGION, 2020-2027($ MILLION)
  • 11. GLOBAL HOSPITALS AND CLINICS RESPIRATORY DRUG MARKET BY REGION, 2020-2027($ MILLION)
  • 12. GLOBAL RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 13. NORTH AMERICAN RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 14. NORTH AMERICAN RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2020-2027($ MILLION)
  • 15. NORTH AMERICAN RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
  • 16. NORTH AMERICAN RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
  • 17. EUROPEAN RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 18. EUROPEAN RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2020-2027($ MILLION)
  • 19. EUROPEAN RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
  • 20. EUROPEAN RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
  • 21. ASIA-PACIFIC RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 22. ASIA-PACIFIC RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BYROUTE OF ADMINISTRATION, 2020-2027($ MILLION)
  • 23. ASIA-PACIFIC RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
  • 24. ASIA-PACIFIC RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
  • 25. REST OF THE WORLD RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BYROUTE OF ADMINISTRATION, 2020-2027($ MILLION)
  • 26. REST OF THE WORLD RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
  • 27. REST OF THE WORLD RESPIRATORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL RESPIRATORY DRUG MARKET RESEARCH, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL RESPIRATORY DRUG MARKET RESEARCH SHARE BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL RESPIRATORY DRUG MARKET RESEARCH, 2021-2027 (%)
  • 4. GLOBAL RESPIRATORY DRUG MARKET RESEARCH SHARE BY ROUTE OF ADMINISTRATION, 2020 VS 2027 (%)
  • 5. GLOBAL RESPIRATORY DRUG MARKET RESEARCH SHARE BY APPLICATION, 2020 VS 2027 (%)
  • 6. GLOBAL RESPIRATORY DRUG MARKET RESEARCH SHARE BY END-USER, 2020 VS 2027 (%)
  • 7. GLOBAL RESPIRATORY DRUG MARKET RESEARCH SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL ORAL RESPIRATORY DRUG MARKET BY REGION, 2020 VS 2027 (%)
  • 9. GLOBAL INJECTABLE RESPIRATORY DRUG MARKET BY REGION, 2020 VS 2027 (%)
  • 10. GLOBAL INHALABLE RESPIRATORY DRUG MARKET BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL ASTHMA RESPIRATORY DRUG MARKET BY REGION, 2020 VS 2027 (%)
  • 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)RESPIRATORY DRUG MARKET BY REGION, 2020 VS 2027 (%)
  • 13. GLOBAL HOMECARE RESPIRATORY DRUG MARKET BY REGION, 2020 VS 2027 (%)
  • 14. GLOBAL HOSPITALS AND CLINICS RESPIRATORY DRUG MARKET BY REGION, 2020 VS 2027 (%)
  • 15. US RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
  • 16. CANADA RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
  • 17. UK RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
  • 18. FRANCE RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
  • 19. GERMANY RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
  • 20. ITALY RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
  • 21. SPAIN RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
  • 22. REST OF EUROPE RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
  • 23. INDIA RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
  • 24. CHINA RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
  • 25. JAPAN RESPIRATORY DRUG MARKET RESEARCH T SIZE, 2020-2027 ($ MILLION)
  • 26. SOUTH KOREA RESPIRATORY DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)
  • 28. REST OF THE WORLD RESPIRATORY DRUG MARKET RESEARCH SIZE, 2020-2027 ($ MILLION)